home / stock / athe / athe news

ATHE News and Press, Alterity Therapeutics Limited From 07/26/23

Stock Information
Company Name: Alterity Therapeutics Limited
Stock Symbol: ATHE
Market: NYSE
Website: alteritytherapeutics.com
Menu
ATHE ATHE Quote ATHE Short ATHE News ATHE Articles ATHE Message Board
Get ATHE Alerts

News, Short Squeeze, Breakout and More Instantly...
ATHE - Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
ATHE - Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...

ATHE - Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

- ATH434 now being evaluated in early and more advanced Multiple System Atrophy - - New trial expected to generate data before ongoing Phase 2 trial - MELBOURNE, Australia and SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“A...

ATHE - Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

MELBOURNE, Australia and SAN FRANCISCO, May 19, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a...
ATHE - Appendix 4C - Q3 FY23 Quarterly Cash Flow Report

Highlights: Continued expansion of ATH434 Phase 2 Clinical Trial with sites open for recruitment in five countries Participants in the US and Europe received first dose as part of the ATH434 Phase 2 Clinical Trial Announced independent study demonstrating that ATH434 prevented t...

ATHE - Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ann...

ATHE - Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

MELBOURNE, Australia and SAN FRANCISCO, April 26, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...
ATHE - Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

ATHE - Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, to...

ATHE - Alterity gets US patent, inks licensing pact to advance asset for Alzheimer's

2023-03-14 08:09:44 ET Alterity Therapeutics ( NASDAQ: ATHE ) said the composition of matter patent previously allowed by the U.S. Patent and Trademark Office (USPTO) was granted by the agency. The patent No. 11,603,364 titled, 'Compounds for and methods of treating dis...
Previous 10 Next 10